Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Catch up Here!

This Webinar took place on 20 November 2024. Catch up by viewing the recording and the presentation slides.

Image ModifiedImage Modified


Recommendations for Adverse Event Collection and Treatment Emergent Definition

In 2019, the PHUSE Best Practices for Data Collection Initiatives project team, in conjunction with the Analysis and Display of Safety Analytics project team, conducted a survey (link) to study the variation in the collection and definition of treatment emergent adverse events (TEAEs) in clinical studies. It noted the need to pursue additional research to further harmonise industry practices. The PHUSE Adverse Event Collection Recommendations and the Treatment Emergent Definitions Recommendations project teams were formed to develop recommendations to reduce the implementation variability.

Adverse Event Collection Recommendations: The PHUSE Adverse Event Collection Recommendations project team developed recommendations for the collection of adverse events which aim to improve the quality of the data and the site experience, as well as provide the data for treatment emergent definitions and for recommended analyses and displays. Earlier this year, the project team issued a white paper (link) documenting the recommendations. This webinar will provide an overview of the white paper, including time for Q&A.

Treatment Emergent Definitions Recommendations : The PHUSE Treatment Emergent Definitions Recommendations project team conducted a survey to solicit input from industry and regulatory respondents on various TEAE scenarios for a simple clinical study design. The project team developed a white paper (link) with recommendations for standardising the TEAE definition based on the survey results, as well as their collective experiences. This webinar will provide an overview of the white paper, including time for Q&A.



PresenterBio

Bill Palo, AbbVie

Bill has been a statistician in the pharmaceutical industry for over 30 years, with half of that time dedicated to product safety analyses. He is currently the safety statistics head for the late-stage oncology portfolio at AbbVie, where the department provides statistical leadership on safety analyses throughout the product life cycle.

Aimee Basile, Otsuka

Aimee Basile has been a data programmer and analyst in the pharmaceutical industry for over 20 years, focusing on the development and management of clinical data standards for the last 15 years. She is currently Director, Clinical Data Standards at Otsuka Pharmaceutical.